Nunoa

This research aims to evaluate the long-term safety and explore the efficacy of astegolimab in adults aged 40 to 90 years with chronic obstructive pulmonary disease COPD. It focuses on participants who have completed a 52-week placebo-controlled treatment period in previous studies GB43311 or GB44332. The study is a phase 3, open-label extension to gather extended safety information on this drug in COPD patients. Participants from the parent studies who qualify will receive subcutaneous injections of astegolimab every two weeks throughout the study until it ends. This open-label extension allows all participants to receive the active drug without placebo comparison. The study continues treatment beyond the initial 52-week period to monitor long-term effects. During the study, participants will be monitored for adverse events up to 12 weeks after their last dose of astegolimab. Researchers will collect safety data to understand the incidence of any side effects. The study involves regular assessments and follow-ups to ensure participant well-being, with the total duration lasting until July 2034.

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and cardiovascular disease but no history of heart failure. The study aims to assess whether this combination can help reduce cardiovascular risks compared to a placebo with empagliflozin. This Phase III trial involves adults with these conditions who are already receiving treatment for them. Participants are randomly assigned to one of two groups. One group takes vicadrostat and empagliflozin tablets daily, while the other group takes placebo tablets that look like vicadrostat but have no active medicine, alongside empagliflozin. Treatment lasts from two and a half years up to four years and three months. All participants continue their usual medications for diabetes, blood pressure, and heart disease during the study. Throughout the study, lasting up to four years and three months, participants visit the study site regularly for health checks and blood samples. Doctors monitor cardiovascular events and any side effects experienced. The main outcome measured is the time until the first cardiovascular death or heart failure event. Other health indicators like blood pressure and kidney function are also tracked to understand the effects of the treatment combination.

Researchers are evaluating the effects of PIPE-791, an oral drug, in adults diagnosed with Idiopathic Pulmonary Fibrosis IPF. This Phase 2, randomized, double-blind, placebo-controlled study aims to assess the efficacy, safety, tolerability, and how the drug moves through the body in participants with IPF, whether or not they are on background treatment. Approximately 324 participants will join this global study to better understand how PIPE-791 may impact lung function in this condition. Participants are randomly assigned to one of three groups two different daily oral doses of PIPE-791 or a matching placebo. The treatment period lasts 26 weeks, during which participants take their assigned tablets daily. The entire study duration can extend up to 36 weeks, including time for screening before treatment begins and follow-up after treatment ends. During the study, participants undergo lung function tests, including measuring forced vital capacity FVC at baseline and various points up to Week 26 to assess changes. Researchers will also monitor safety and side effects through reported adverse events up to Week 30. Additional assessments include lung imaging with high-resolution CT scans and other lung function measures. Participants will be followed throughout the study with scheduled visits to collect data on how they respond to the treatments and any potential side effects.